Amgen is a pioneer in the science of using living cells to make biologic medicines. We helped invent the processes and tools that built the global biotech industry—turning it into a leading source of therapies for patients facing serious illness.
Some of the greatest advances in science are taking place now inside Amgen. Watch and hear the stories from the scientists making it happen.
Since 1980, scientists at Amgen have devoted themselves to providing novel therapies for patients with serious illnesses. Amgen’s growth from a biotech pioneer to an industry leader reflects their strong desire to make a difference and the company’s commitment to be science-driven.
This commitment has attracted world-class research talent and forged new ways to address the molecular causes of disease. Amgen has delivered important new therapies for hard-to-treat disease, including cancer, kidney failure, blood disorders, autoimmune, and bone diseases. We are building on these successes with a drug pipeline that aims to give patients in need even better options than they have now.
You can find out more about Amgen’s pipeline, science and biotechnology by tapping into the web resources section (top right of the menu bar) and following the links or by selecting the videos and items below.
Amgen has built an organization distinguished by world-class scientists with a talent for applying novel approaches to treat disease. Our R&D strategy aims to align and engage our talent, prioritize investments, and seize scientific opportunities.
Australian patients have access to Amgen’s medicines through clinical trials, which have been conducted in Australia for over 25 years.
Amgen has created a robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illnesses.
At Amgen, we continually invest in our manufacturing to strengthen our industry-leading capabilities and extend our global reach. Our commitment is to ensure that all our medicines are available for "every patient, every time."